

# Antonio Pisani

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7296337/antonio-pisani-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

178  
papers

5,359  
citations

39  
h-index

68  
g-index

183  
ext. papers

6,206  
ext. citations

4.9  
avg, IF

5.35  
L-index

#	Paper	IF	Citations
178	The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease.. <i>European Radiology</i> , <b>2022</b> , 1	8	1
177	RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9, 824095	5.4	0
176	Diagnosis and Management of Cardiovascular Involvement in Fabry Disease. <i>Heart Failure Clinics</i> , <b>2022</b> , 18, 39-49	3.3	4
175	Predictive effect of salt intake on patient and kidney survival in non-dialysis CKD: competing risk analysis in older versus younger patients under nephrology care. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> , 36, 2232-2240	4.3	2
174	Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol. <i>Molecular Genetics &amp; Genomic Medicine</i> , <b>2021</b> , 9, e1659	2.3	1
173	Nonvascular Parkinsonism in Fabry Disease: Results From Magnetic Resonance and Dopamine Transporter Imaging. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2021</b> , 80, 476-479	3.1	1
172	Therapeutic advances in ADPKD: the future awaits. <i>Journal of Nephrology</i> , <b>2021</b> , 1	4.8	1
171	Vesicular Acetylcholine Transporter Alters Cholinergic Tone and Synaptic Plasticity in DYT1 Dystonia. <i>Movement Disorders</i> , <b>2021</b> ,	7	1
170	Focal reduction in left ventricular I-metaiodobenzylguanidine uptake and impairment in systolic function in patients with Anderson-Fabry disease. <i>Journal of Nuclear Cardiology</i> , <b>2021</b> , 28, 641-649	2.1	3
169	Does left ventricular function predict cardiac outcome in Anderson-Fabry disease?. <i>International Journal of Cardiovascular Imaging</i> , <b>2021</b> , 37, 1225-1236	2.5	3
168	Darbepoetin alfa reduces cell death due to radiocontrast media in human renal proximal tubular cells. <i>Toxicology Reports</i> , <b>2021</b> , 8, 816-821	4.8	0
167	Potential resistance to SARS-CoV-2 infection in lysosomal storage disorders. <i>CKJ: Clinical Kidney Journal</i> , <b>2021</b> , 14, 1488-1490	4.5	1
166	DNA methylation impact on Fabry disease. <i>Clinical Epigenetics</i> , <b>2021</b> , 13, 24	7.7	3
165	Striatal and cerebellar vesicular acetylcholine transporter expression is disrupted in human DYT1 dystonia. <i>Brain</i> , <b>2021</b> , 144, 909-923	11.2	7
164	The Role of Immunosuppressive Therapy in Aneurysmal Degeneration of Hemodialysis Fistulas in Renal Transplant Patients. <i>Annals of Vascular Surgery</i> , <b>2021</b> , 74, 21-28	1.7	1
163	Role of serial cardiac F-FDG PET-MRI in Anderson-Fabry disease: a pilot study. <i>Insights Into Imaging</i> , <b>2021</b> , 12, 124	5.6	0
162	The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , <b>2021</b> , 11, 23500	4.9	1

161	Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson-Fabry disease.. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 1150	9.8	1
160	Multimodality imaging approach to Fabry cardiomyopathy: Any role for nuclear cardiology?. <i>Journal of Nuclear Cardiology</i> , <b>2020</b> , 1	2.1	1
159	Acute Kidney Injury in COVID-19 Pandemic. <i>Nephron</i> , <b>2020</b> , 144, 345-346	3.3	3
158	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases. <i>PLoS ONE</i> , <b>2020</b> , 15, e0233050	3.7	8
157	COVID-19 Experience in Hemodialysis Patients: A Cue for Therapeutic Heparin-Based Strategies?. <i>Nephron</i> , <b>2020</b> , 144, 383-385	3.3	4
156	Oral Sucrosomial <sup>®</sup> iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis. <i>BMC Nephrology</i> , <b>2020</b> , 21, 57	2.7	5
155	Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis. <i>Molecular Genetics and Metabolism</i> , <b>2020</b> , 129, 132-141	3.7	9
154	Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995-2019. <i>Journal of Nephrology</i> , <b>2020</b> , 33, 569-581	4.8	9
153	Early Predictors of Arteriovenous Fistula Maturation: Preoperative Arterial Diameter Alone Is Not Enough. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2020</b> , 31, 2226-2228	12.7	1
152	Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data. <i>European Journal of Human Genetics</i> , <b>2020</b> , 28, 1662-1668	5.3	14
151	Microstructural damage of the cortico-striatal and thalamo-cortical fibers in Fabry disease: a diffusion MRI tractometry study. <i>Neuroradiology</i> , <b>2020</b> , 62, 1459-1466	3.2	3
150	Impact of COVID-19 pandemic on patients with Fabry disease: An Italian experience. <i>Molecular Genetics and Metabolism</i> , <b>2020</b> , 131, 124-125	3.7	7
149	Association between Left Atrial Deformation and Brain Involvement in Patients with Anderson-Fabry Disease at Diagnosis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4
148	The Retinal Vessel Density as a New Vascular Biomarker in Multisystem Involvement in Fabry Disease: An Optical Coherence Tomography Angiography Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	5
147	Renal Denervation for Resistant Hypertension: Time to Improve Patient Selection. The Lesson From ADPKD. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 604384	4.9	
146	MALDI imaging in Fabry nephropathy: a multicenter study. <i>Journal of Nephrology</i> , <b>2020</b> , 33, 299-306	4.8	1
145	Left ventricular radial strain impairment precedes hypertrophy in Anderson-Fabry disease. <i>International Journal of Cardiovascular Imaging</i> , <b>2020</b> , 36, 1465-1476	2.5	1
144	Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study. <i>Journal of the Neurological Sciences</i> , <b>2020</b> , 412, 116782	3.2	1

143	The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts. <i>Orphanet Journal of Rare Diseases</i> , <b>2020</b> , 15, 86	4.2	2
142	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases <b>2020</b> , 15, e0233050		
141	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases <b>2020</b> , 15, e0233050		
140	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases <b>2020</b> , 15, e0233050		
139	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases <b>2020</b> , 15, e0233050		
138	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases <b>2020</b> , 15, e0233050		
137	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases <b>2020</b> , 15, e0233050		
136	Optical Coherence Tomography Angiography Findings in Fabry Disease. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	14
135	Hybrid positron emission tomography-magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Anderson-Fabry disease: AFFINITY study group. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2019</b> , 20, 1004-1011	4.1	17
134	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002777	11.6	21
133	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1177-1190	6.7	9
132	Prominent longitudinal strain reduction of left ventricular basal segments in treatment-naïve Anderson-Fabry disease patients. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2019</b> , 20, 438-445	4.1	26
131	Dystonia and dopamine: From phenomenology to pathophysiology. <i>Progress in Neurobiology</i> , <b>2019</b> , 182, 101678	10.9	24
130	ADPKD and metformin: from bench to bedside. <i>Clinical and Experimental Nephrology</i> , <b>2019</b> , 23, 1341-1342	2.5	5
129	Layer-specific longitudinal strain in Anderson-Fabry disease at diagnosis: A speckle tracking echocardiography analysis. <i>Echocardiography</i> , <b>2019</b> , 36, 1273-1281	1.5	10
128	Early Biomarkers of Fabry Nephropathy: A Review of the Literature. <i>Nephron</i> , <b>2019</b> , 143, 274-281	3.3	12
127	Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report. <i>BMC Nephrology</i> , <b>2019</b> , 20, 426	2.7	4
126	New insights from the application of the FABry STabilization indEX in a large population of Fabry cases. <i>CKJ: Clinical Kidney Journal</i> , <b>2019</b> , 12, 65-70	4.5	7

125	Glomerular Hyperfiltration: An Early Marker of Nephropathy in Fabry Disease. <i>Nephron</i> , <b>2019</b> , 141, 10-17	3.3	12
124	Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial. <i>International Journal of Cardiology</i> , <b>2019</b> , 275, 145-151	3.2	10
123	Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying Galactosidase A Mutation: Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-Tracking Echocardiography. <i>Circulation: Cardiovascular Imaging</i> , <b>2018</b> , 11, e007019	3.9	21
122	Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus. <i>Journal of Neural Transmission</i> , <b>2018</b> , 125, 673-679	4.3	20
121	Motor involvement in Fabry disease. <i>Molecular Genetics and Metabolism Reports</i> , <b>2018</b> , 14, 43	1.8	4
120	Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations. <i>Human Brain Mapping</i> , <b>2018</b> , 39, 1755-1764	5.9	18
119	Parapelvic cysts, a distinguishing feature of renal Fabry disease. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, 318-323	4.3	12
118	Quercetin protects against radiocontrast medium toxicity in human renal proximal tubular cells. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 4116-4125	7	10
117	Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 57, 27-32	3.6	9
116	A pilot study of circulating microRNAs as potential biomarkers of Fabry disease. <i>Oncotarget</i> , <b>2018</b> , 9, 27333-27345	3.3	15
115	Diagnostic Clues for the Diagnosis of Nonsarcomeric Hypertrophic Cardiomyopathy (Phenocopies): Amyloidosis, Fabry Disease, and Mitochondrial Disease. <i>Journal of Cardiovascular Echography</i> , <b>2018</b> , 28, 120-123	0.6	6
114	Enhanced mu opioid receptor-dependent opioidergic modulation of striatal cholinergic transmission in DYT1 dystonia. <i>Movement Disorders</i> , <b>2018</b> , 33, 310-320	7	10
113	Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial. <i>Clinical and Experimental Nephrology</i> , <b>2018</b> , 22, 529-538	2.5	16
112	An unusual case of tuberous sclerosis incidentally discovered in adulthood: case report and review of the literature. <i>Acta Radiologica Open</i> , <b>2018</b> , 7, 2058460118806328	1.2	1
111	Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients. <i>Data in Brief</i> , <b>2018</b> , 21, 2075-2081	1.2	4
110	Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	37
109	Neuroimaging in Fabry disease: current knowledge and future directions. <i>Insights Into Imaging</i> , <b>2018</b> , 9, 1077-1088	5.6	22
108	Multiple sclerosis and fabry Disease, two sides of the coin? The case of an Italian Family. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 26, 164-167	4	4

107	Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis. <i>Brain and Behavior</i> , <b>2018</b> , 8, e01121	3.4	10
106	Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?. <i>BMC Nephrology</i> , <b>2018</b> , 19, 282	2.7	20
105	Reduced Intracranial Volume in Fabry Disease: Evidence of Abnormal Neurodevelopment?. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 672	4.1	6
104	Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis. <i>Neuroradiology</i> , <b>2017</b> , 59, 563-570	3.2	24
103	Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study. <i>Neurology</i> , <b>2017</b> , 88, 1822-1829	6.5	15
102	The ischemic/nephrotoxic acute kidney injury and the use of renal biomarkers in clinical practice. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 39, 1-8	3.9	61
101	Author response: Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study. <i>Neurology</i> , <b>2017</b> , 89, 1842-1843	6.5	
100	Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. <i>BioMed Research International</i> , <b>2017</b> , 2017, 7869802	3	58
99	Genetic variants associated with Fabry disease progression despite enzyme replacement therapy. <i>Oncotarget</i> , <b>2017</b> , 8, 107558-107564	3.3	22
98	Effect of a Short-Course Treatment with Synbiotics on Plasma p-Cresol Concentration in Kidney Transplant Recipients. <i>Journal of the American College of Nutrition</i> , <b>2017</b> , 36, 586-591	3.5	16
97	Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 1059-1067	3.7	2
96	Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 2266-2273	8.8	21
95	Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease. <i>Future Cardiology</i> , <b>2017</b> , 13, 521-527	1.3	2
94	Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review. <i>Aging Clinical and Experimental Research</i> , <b>2017</b> , 29, 73-78	4.8	15
93	Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature. <i>Genetics in Medicine</i> , <b>2017</b> , 19, 275-282	8.1	5
92	Parapelvic Cysts: A Suspicious Feature of Fabry Disease. <i>Giornale De Tecniche Nefrologiche &amp; Dialitiche</i> , <b>2017</b> , 29, 101-102	0	
91	Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review. <i>BioMed Research International</i> , <b>2017</b> , 2017, 2605628	3	27
90	6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial. <i>Clinical and Experimental Nephrology</i> , <b>2016</b> , 20, 433-42	2.5	22

89	Hyperkinetic disorders and loss of synaptic downscaling. <i>Nature Neuroscience</i> , <b>2016</b> , 19, 868-75	25.5	70
88	Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. <i>Journal of Nephrology</i> , <b>2016</b> , 29, 71-8	4.8	16
87	What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review. <i>International Journal of Surgery</i> , <b>2016</b> , 28 Suppl 1, S172-6	7.5	13
86	Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123)I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 729-39	8.8	10
85	Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1022-1030.e4	6.9	33
84	Molecular and clinical studies in five index cases with novel mutations in the GLA gene. <i>Gene</i> , <b>2016</b> , 578, 100-4	3.8	15
83	Genetic variants associated with gastrointestinal symptoms in Fabry disease. <i>Oncotarget</i> , <b>2016</b> , 7, 85895-85904	3.5	45
82	The potential use of biomarkers in predicting contrast-induced acute kidney injury. <i>International Journal of Nephrology and Renovascular Disease</i> , <b>2016</b> , 9, 205-21	2.5	32
81	Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial. <i>PLoS ONE</i> , <b>2015</b> , 10, e0118174	3.7	24
80	Atrial septum aneurysm: an unusual manifestation in ADPKD?. <i>Clinical and Experimental Nephrology</i> , <b>2015</b> , 19, 1206-7	2.5	
79	Rhes regulates dopamine D2 receptor transmission in striatal cholinergic interneurons. <i>Neurobiology of Disease</i> , <b>2015</b> , 78, 146-61	7.5	19
78	First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 1025-31	8.8	57
77	Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 645-52	4.3	86
76	Nutritional treatment in chronic kidney disease: the concept of nephroprotection. <i>Clinical and Experimental Nephrology</i> , <b>2015</b> , 19, 161-7	2.5	14
75	Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease. <i>BMC Research Notes</i> , <b>2015</b> , 8, 711	2.3	5
74	A clinical and biochemical analysis in the differential diagnosis of idiopathic normal pressure hydrocephalus. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 86	4.1	31
73	Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. <i>BioMed Research International</i> , <b>2015</b> , 2015, 183523	3	13
72	Pituitary function and morphology in Fabry disease. <i>Endocrine</i> , <b>2015</b> , 50, 483-8	4	4

71	Reversal of radiocontrast medium toxicity in human renal proximal tubular cells by white grape juice extract. <i>Chemico-Biological Interactions</i> , <b>2015</b> , 229, 17-25	5	19
70	Antiproteinuric effect of add-on paricalcitol in Fabry disease patients: a prospective observational study. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 661-6	4.3	16
69	Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?. <i>Genetics in Medicine</i> , <b>2015</b> , 17, 21-3	8.1	3
68	Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and agalsidase alpha in cultured fibroblasts from patients with Fabry disease. <i>Journal of Inherited Metabolic Disease</i> , <b>2014</b> , 37, 145-6	5.4	5
67	Renal sympathetic-nerve ablation for uncontrolled hypertension in a patient with single-kidney autosomal dominant polycystic kidney disease. <i>Journal of Clinical Hypertension</i> , <b>2014</b> , 16, 385-6	2.3	9
66	Fanconi syndrome with lysinuric protein intolerance. <i>CKJ: Clinical Kidney Journal</i> , <b>2014</b> , 7, 599-601	4.5	8
65	Arterial aneurysms: autosomal dominant polycystic kidney disease, Marfan syndrome or both?. <i>Clinical and Experimental Nephrology</i> , <b>2014</b> , 18, 672-3	2.5	1
64	Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 850-63	12.7	147
63	Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. <i>American Journal of Physiology - Renal Physiology</i> , <b>2014</b> , 306, F1243-50	4.3	15
62	Differential activation of signaling pathways by low-osmolar and iso-osmolar radiocontrast agents in human renal tubular cells. <i>Journal of Cellular Biochemistry</i> , <b>2014</b> , 115, 281-9	4.7	29
61	Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury. <i>Clinical and Experimental Nephrology</i> , <b>2014</b> , 18, 424-31	2.5	39
60	Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors. <i>Scientific World Journal, The</i> , <b>2014</b> , 2014, 823169	2.2	68
59	The Choice of the Iodinated Radiographic Contrast Media to Prevent Contrast-Induced Nephropathy. <i>Advances in Nephrology</i> , <b>2014</b> , 2014, 1-11		8
58	Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: role of M1 muscarinic receptors. <i>Movement Disorders</i> , <b>2014</b> , 29, 1655-65	7	69
57	Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study. <i>Patient Preference and Adherence</i> , <b>2014</b> , 8, 73-81	2.4	28
56	Acute kidney injury by radiographic contrast media: pathogenesis and prevention. <i>BioMed Research International</i> , <b>2014</b> , 2014, 362725	3	77
55	Endothelial-mediated coronary flow reserve in patients with Anderson-Fabry disease. <i>International Journal of Cardiology</i> , <b>2014</b> , 177, 1059-60	3.2	1
54	Catheter-based renal denervation in ADPKD: just for pain control?. <i>American Journal of Kidney Diseases</i> , <b>2014</b> , 64, 999	7.4	3



53	Molecular mechanisms of renal cellular nephrotoxicity due to radiocontrast media. <i>BioMed Research International</i> , <b>2014</b> , 2014, 249810	3	29
52	Pleural effusion in peritoneal dialysis: overload or leakage?. <i>Clinical and Experimental Nephrology</i> , <b>2013</b> , 17, 907	2.5	1
51	Polycystic horseshoe kidney. <i>Clinical and Experimental Nephrology</i> , <b>2013</b> , 17, 905-6	2.5	1
50	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. <i>Lancet, The</i> , <b>2013</b> , 382, 1485-95	40	180
49	Role of reactive oxygen species in pathogenesis of radiocontrast-induced nephropathy. <i>BioMed Research International</i> , <b>2013</b> , 2013, 868321	3	61
48	Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. <i>Molecular Genetics and Metabolism</i> , <b>2012</b> , 107, 267-75	3.7	71
47	A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report. <i>BMC Cardiovascular Disorders</i> , <b>2012</b> , 12, 39	2.3	15
46	Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. <i>Journal of Neuroinflammation</i> , <b>2012</b> , 9, 188	10.1	92
45	How relevant is the cholinergic system in DYT1 dystonia?. <i>Basal Ganglia</i> , <b>2012</b> , 2, 227-230		
44	Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study. <i>PLoS ONE</i> , <b>2012</b> , 7, e32533	3.7	39
43	Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. <i>Journal of Inherited Metabolic Disease</i> , <b>2012</b> , 35, 513-20	5.4	37
42	Cholinergic dysfunction alters synaptic integration between thalamostriatal and corticostriatal inputs in DYT1 dystonia. <i>Journal of Neuroscience</i> , <b>2012</b> , 32, 11991-2004	6.6	76
41	Nephrotic syndrome and autosomal dominant polycystic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , <b>2012</b> , 5, 508-11	4.5	6
40	Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. <i>Nephrology Dialysis Transplantation</i> , <b>2012</b> , 27, 3560-7	4.3	41
39	A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency. <i>Journal of Nephrology</i> , <b>2012</b> , 25, 582-5	4.8	1
38	Abnormal plasticity in dystonia: Disruption of synaptic homeostasis. <i>Neurobiology of Disease</i> , <b>2011</b> , 42, 162-70	7.5	105
37	Centrality of striatal cholinergic transmission in Basal Ganglia function. <i>Frontiers in Neuroanatomy</i> , <b>2011</b> , 5, 6	3.6	91
36	Experimental models of dystonia. <i>International Review of Neurobiology</i> , <b>2011</b> , 98, 551-72	4.4	10

35	Clinical treatment of polycystic kidney disease (APKD): do we need further suggestions from rodents?. <i>Nephrology Dialysis Transplantation</i> , <b>2011</b> , 26, 2065-6	4.3	2
34	Differential activation of signaling pathways involved in cell death, survival and inflammation by radiocontrast media in human renal proximal tubular cells. <i>Toxicological Sciences</i> , <b>2011</b> , 119, 408-16	4.4	39
33	Developmental profile of the aberrant dopamine D2 receptor response in striatal cholinergic interneurons in DYT1 dystonia. <i>PLoS ONE</i> , <b>2011</b> , 6, e24261	3.7	60
32	Simultaneous multicystic kidney and Anderson-Fabry disease: 2 separate entities or same side of the coin. <i>Journal of Nephrology</i> , <b>2011</b> , 24, 806-8	4.8	4
31	Effects of mycophenolate mofetil on acute ischaemia-reperfusion injury in rats and its consequences in the long term. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 1443-50	4.3	8
30	Electrophysiology of 5-HT6 receptors. <i>International Review of Neurobiology</i> , <b>2010</b> , 94, 111-28	4.4	7
29	Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells. <i>Chemico-Biological Interactions</i> , <b>2010</b> , 185, 253-62	5	29
28	Setting dialysis start at 6.0 ml/min/1.73 m2 eGFR—a study on safety, quality of life and economic impact. <i>Nephrology Dialysis Transplantation</i> , <b>2009</b> , 24, 3434-40	4.3	19
27	Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. <i>Brain</i> , <b>2009</b> , 132, 2336-49	11.2	166
26	Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia. <i>Neurobiology of Disease</i> , <b>2009</b> , 34, 133-45	7.5	63
25	Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial. <i>American Journal of Kidney Diseases</i> , <b>2009</b> , 54, 1052-61	7.4	51
24	EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. <i>Fundamental and Clinical Pharmacology</i> , <b>2009</b> , 23, 617-24	3.1	25
23	Cholinergic Interneuron and Parkinsonism <b>2009</b> , 1-11		
22	Sleep quality in patients with chronic renal failure: a 3-year longitudinal study. <i>Sleep Medicine</i> , <b>2008</b> , 9, 240-6	4.6	39
21	Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. <i>Nephrology Dialysis Transplantation</i> , <b>2008</b> , 23, 1628-35	4.3	41
20	Loss of muscarinic autoreceptor function impairs long-term depression but not long-term potentiation in the striatum. <i>Journal of Neuroscience</i> , <b>2008</b> , 28, 6258-63	6.6	75
19	Metabolic effects of two low protein diets in chronic kidney disease stage 4-5—a randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , <b>2008</b> , 23, 636-44	4.3	76
18	Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 1840-54	8.7	112

17	MRI characterization of myocardial tissue in patients with Fabry disease. <i>American Journal of Roentgenology</i> , <b>2007</b> , 188, 850-3	5.4	29
16	Re-emergence of striatal cholinergic interneurons in movement disorders. <i>Trends in Neurosciences</i> , <b>2007</b> , 30, 545-53	13.3	343
15	Inhibition of Ras/ERK1/2 signaling protects against postischemic renal injury. <i>American Journal of Physiology - Renal Physiology</i> , <b>2006</b> , 290, F1408-15	4.3	37
14	Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. <i>American Journal of Kidney Diseases</i> , <b>2005</b> , 46, 120-7	7.4	56
13	Sleep quality in renal transplant patients: a never investigated problem. <i>Nephrology Dialysis Transplantation</i> , <b>2005</b> , 20, 194-8	4.3	71
12	Coordinate high-frequency pattern of stimulation and calcium levels control the induction of LTP in striatal cholinergic interneurons. <i>Learning and Memory</i> , <b>2004</b> , 11, 755-60	2.8	23
11	Atorvastatin improves the course of ischemic acute renal failure in aging rats. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2004</b> , 15, 901-9	12.7	62
10	The impact of haemoglobin on the quality of sleep in haemodialysis patients: which is the truth?. <i>Nephrology Dialysis Transplantation</i> , <b>2003</b> , 18, 1947-8; author reply 1948	4.3	6
9	Arginase inhibition slows the progression of renal failure in rats with renal ablation. <i>American Journal of Physiology - Renal Physiology</i> , <b>2003</b> , 284, F680-7	4.3	17
8	Zaleplon improves sleep quality in maintenance hemodialysis patients. <i>Nephron Clinical Practice</i> , <b>2003</b> , 94, c99-103		27
7	Insomnia in maintenance haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , <b>2002</b> , 17, 852-6	4.3	117
6	Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. <i>American Journal of Kidney Diseases</i> , <b>2001</b> , 38, 18-25	7.4	217
5	Activation of D2-like dopamine receptors reduces synaptic inputs to striatal cholinergic interneurons. <i>Journal of Neuroscience</i> , <b>2000</b> , 20, RC69	6.6	131
4	Acetylcholine-mediated modulation of striatal function. <i>Trends in Neurosciences</i> , <b>2000</b> , 23, 120-6	13.3	360
3	Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. <i>American Journal of Kidney Diseases</i> , <b>1999</b> , 33, 851-6	7.4	200
2	Muscarinic IPSPs in rat striatal cholinergic interneurons. <i>Journal of Physiology</i> , <b>1998</b> , 510 ( Pt 2), 421-7	3.9	75
1	Animal Models of Dystonia49-52		